Abstract
In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.
| Original language | English |
|---|---|
| Pages (from-to) | 68-70 |
| Number of pages | 3 |
| Journal | Nature Reviews Nephrology |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Feb 2019 |
Cite this
}
A promising outlook for diabetic kidney disease. / Cooper, Mark; Warren, Annabelle M.
In: Nature Reviews Nephrology, Vol. 15, No. 2, 01.02.2019, p. 68-70.Research output: Contribution to journal › Article › Other › peer-review
TY - JOUR
T1 - A promising outlook for diabetic kidney disease
AU - Cooper, Mark
AU - Warren, Annabelle M.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.
AB - In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.
UR - http://www.scopus.com/inward/record.url?scp=85058272196&partnerID=8YFLogxK
U2 - 10.1038/s41581-018-0092-5
DO - 10.1038/s41581-018-0092-5
M3 - Article
VL - 15
SP - 68
EP - 70
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
SN - 1759-5061
IS - 2
ER -